scPharmaceuticals Inc.
SCPH
$4.85
$0.286.13%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 16.04M | 11.75M | 12.15M | 10.03M | 8.05M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 16.04M | 11.75M | 12.15M | 10.03M | 8.05M |
| Cost of Revenue | 5.01M | 3.47M | 3.97M | 3.31M | 2.30M |
| Gross Profit | 11.03M | 8.28M | 8.19M | 6.72M | 5.75M |
| SG&A Expenses | 21.23M | 21.41M | 21.37M | 21.32M | 17.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.34M | 29.51M | 28.49M | 28.17M | 22.49M |
| Operating Income | -14.29M | -17.76M | -16.34M | -18.15M | -14.43M |
| Income Before Tax | -18.02M | -19.74M | -18.85M | -35.11M | -17.09M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.02M | -19.74M | -18.85M | -35.11M | -17.09M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.02M | -19.74M | -18.85M | -35.11M | -17.09M |
| EBIT | -14.29M | -17.76M | -16.34M | -18.15M | -14.43M |
| EBITDA | -14.29M | -17.75M | -16.34M | -18.14M | -14.43M |
| EPS Basic | -0.34 | -0.37 | -0.35 | -0.75 | -0.44 |
| Normalized Basic EPS | -0.21 | -0.23 | -0.22 | -0.49 | -0.27 |
| EPS Diluted | -0.34 | -0.37 | -0.35 | -0.75 | -0.44 |
| Normalized Diluted EPS | -0.21 | -0.23 | -0.22 | -0.49 | -0.27 |
| Average Basic Shares Outstanding | 53.72M | 53.68M | 53.46M | 46.56M | 38.98M |
| Average Diluted Shares Outstanding | 53.72M | 53.68M | 53.46M | 46.56M | 38.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |